Physician profile
Charles E Bramlet
NPI 1457438947
$1,994.84
in general payments reported to CMS, 2019-2025
18 companies · $554 in 2025
The $554 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $290 · 2023: $586 · 2024: $565 · 2025: $554.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,705.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,704.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $389.12 | 2023-2025 | Rexulti |
| Noven Therapeutics, LLC | $338.99 | 2023-2025 | Xelstrym, Secuado |
| Axsome Therapeutics, INC. | $187.96 | 2022-2024 | Auvelity |
| Neurocrine Biosciences, INC. | $144.38 | 2022 | |
| Abbvie INC. | $133.03 | 2023-2025 | Vraylar |
| Alkermes, INC. | $123.58 | 2023-2025 | Aristada, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $114.67 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $105.73 | 2022-2025 | Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $101.11 | 2024-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $87.89 | 2024-2025 | Fanapt |
| Supernus Pharmaceuticals, INC. | $57.48 | 2024-2025 | Qelbree |
| Corium, LLC | $53.07 | 2023-2025 | Azstarys |
| Neos Therapeutics, Lp | $45.42 | 2024-2025 | Adzenys Xr-Odt, Exxua |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $38.62 | 2023-2024 | Caplyta |
| Vertical Pharmaceuticals, LLC | $21.19 | 2025 | Relexxii |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $19.36 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $18.88 | 2022 | |
| Tris Pharma INC | $14.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Bramlet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.